Actavis To Host Third Quarter 2014 Earnings Conference Call And Webcast

DUBLIN, Sept. 30, 2014 /PRNewswire/ -- Actavis plc (NYSE: ACT) today announced that it intends to release third quarter 2014 financial results on Wednesday, November 5, 2014, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:00 a.m. Eastern Standard Time on Wednesday, November 5, 2014 to discuss its financial results. The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 8164798.

Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO

A taped replay of the conference call will also be available beginning approximately two hours after the call’s conclusion and will remain available through 12:00 midnight Eastern Time on November 19, 2014. The replay may be accessed by dialing (855) 859-2056 and entering Conference ID# 8164798. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same Conference ID#. To access the webcast, go to Actavis’ Investor Relations Web site at http://ir.actavis.com. A replay of the webcast will also be available.

About Actavis
Actavis plc (NYSE:ACT), headquartered in Dublin, Ireland, is a unique specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world.

Actavis markets a broad portfolio of branded and generic pharmaceuticals and develops innovative medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. The Company is an industry leader in product research and development, with one of the broadest brand development pipelines in the pharmaceutical industry, and a leading position in the submission of generic product applications. Actavis has commercial operations in more than 60 countries and operates more than 30 manufacturing and distribution facilities around the world.

For more information, visit Actavis’ website at www.actavis.com.

SOURCE Actavis plc